|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Pharmaceutical Executive, January 2022 Issue (PDF)
Advertisement
Articles in this issue
over 4 years ago
Keeping Tabs on Quality: The Rise of Digitalover 4 years ago
China Invests in Building Biotechover 4 years ago
Branding Takes on a New Lookover 4 years ago
Addressing Access Burdensover 4 years ago
Meeting the Patient—Virtuallyover 4 years ago
The Age of Influenceover 4 years ago
Boosting Immunotherapiesover 4 years ago
Pharma’s Psychedelic Experienceover 4 years ago
Supply Chain Procurementover 4 years ago
Our View on 2022: Pharm Exec’s Annual Industry OutlookAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
4
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
5